We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OPKO Health, Inc.’s (OPK - Free Report) subsidiary, BioReference Laboratories, Inc., recently collaborated with MagnaCare — a division of Brighton Health Plans Solutions, LLC — to offer COVID-19 antibody testing to Labor clients in the New York metropolitan area. With this antibody testing, Labor groups in the area will be able to gather information and take decisions regarding back-to-work procedures and safety measures for the protection of workers and the public.
Notably, BioReference Laboratories provides detection, diagnosis, evaluation, monitoring and treatment of diseases. Consequently, the latest move is likely to strengthen OPKO’s presence in theinfectious disease diagnostics market.
Importance of Antibody Testing
OPKO’s BioReference Laboratories has been working closely with New York State and New York City to bring in antibody testing given the widespread COVID-19 outbreak across New York, which made it the epicenter of the outbreak in the United States.
BioReference Laboratories provides a blood test that measures SARS-CoV-2 specific antibody levels to help identify an individual’s immune response after COVID-19 infection.
The primary objective of this collaboration is to provide comfort, safety and confidence to the Labor groups.
Other Developments
On May 8, BioReference Laboratories launched COVID-19 antibody screening for New York City residents in collaboration with New York City Health and Hospital Corporation. At first, testing will be done for 140,000 residents at five locations throughout all five boroughs with more testing sites to open in the next several weeks.
On May 13, BioReference Laboratories introduced the BioReference Employer Solution, which is a COVID-19 screening program that helps employers' decisions about return-to-work policies.
Market Prospects
A report by MarketsandMarkets estimates the global infectious disease diagnostics market to reach a worth of $19.35 billion in 2022 witnessing a CAGR of 5.6%.
Price Performance
Shares of this Zacks Rank #2 (Buy) stock gained 38.2% in a year’s time, outperforming the industry’s growth of 7.7%.
Aphria has an estimated long-term earnings growth rate of 24.6%.
HMS Holdings has an estimated long-term earnings growth rate of 11%.
West Pharmaceutical has a projected long-term earnings growth rate of 9.2%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
OPKO's BioReference Laboratories' Deal Brings Antibody Testing
OPKO Health, Inc.’s (OPK - Free Report) subsidiary, BioReference Laboratories, Inc., recently collaborated with MagnaCare — a division of Brighton Health Plans Solutions, LLC — to offer COVID-19 antibody testing to Labor clients in the New York metropolitan area. With this antibody testing, Labor groups in the area will be able to gather information and take decisions regarding back-to-work procedures and safety measures for the protection of workers and the public.
Notably, BioReference Laboratories provides detection, diagnosis, evaluation, monitoring and treatment of diseases. Consequently, the latest move is likely to strengthen OPKO’s presence in theinfectious disease diagnostics market.
Importance of Antibody Testing
OPKO’s BioReference Laboratories has been working closely with New York State and New York City to bring in antibody testing given the widespread COVID-19 outbreak across New York, which made it the epicenter of the outbreak in the United States.
BioReference Laboratories provides a blood test that measures SARS-CoV-2 specific antibody levels to help identify an individual’s immune response after COVID-19 infection.
The primary objective of this collaboration is to provide comfort, safety and confidence to the Labor groups.
Other Developments
On May 8, BioReference Laboratories launched COVID-19 antibody screening for New York City residents in collaboration with New York City Health and Hospital Corporation. At first, testing will be done for 140,000 residents at five locations throughout all five boroughs with more testing sites to open in the next several weeks.
On May 13, BioReference Laboratories introduced the BioReference Employer Solution, which is a COVID-19 screening program that helps employers' decisions about return-to-work policies.
Market Prospects
A report by MarketsandMarkets estimates the global infectious disease diagnostics market to reach a worth of $19.35 billion in 2022 witnessing a CAGR of 5.6%.
Price Performance
Shares of this Zacks Rank #2 (Buy) stock gained 38.2% in a year’s time, outperforming the industry’s growth of 7.7%.
Key Picks
Some other top-ranked stocks from the broader medical space include Aphria Inc. , HMS Holdings Corp. and West Pharmaceutical Services, Inc. (WST - Free Report) , each currently carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aphria has an estimated long-term earnings growth rate of 24.6%.
HMS Holdings has an estimated long-term earnings growth rate of 11%.
West Pharmaceutical has a projected long-term earnings growth rate of 9.2%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>